We are live on ! Find out more
HAIM

Hunter Associates Investment Management Portfolio holdings

AUM $868M
1-Year Est. Return 32.25%
This Fund
S&P 500
This Quarter Est. Return
+6.91%
1 Year Est. Return
+32.25%
3 Year Est. Return
+76.06%
5 Year Est. Return
+90.53%
10 Year Est. Return
+362.12%
AUM
$271M
AUM Growth
+$14.8M
Cap. Flow
-$109K
Cap. Flow %
-0.04%
Top 10 Hldgs %
32.4%
Holding
170
New
10
Increased
48
Reduced
63
Closed
6

Top Buys

Rank Stock Value
1
APTV icon
Aptiv
APTV
+$3.13M
2
AMGN icon
Amgen
AMGN
+$1.13M
3
DLR icon
Digital Realty Trust
DLR
+$366K
4
TRIB
Trinity Biotech
TRIB
+$362K
5
WRK
WestRock Company
WRK
+$332K

Sector Composition

Rank Sector Weight
1 Healthcare 23.01%
2 Technology 21.3%
3 Industrials 15.13%
4 Consumer Staples 9.12%
5 Financials 8.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TPL icon
51
Texas Pacific Land
TPL
$24.2B
$1.31M 0.48%
26,370
+270
+1% +$12.3K
PNC icon
52
PNC Financial Services
PNC
$100B
$1.3M 0.48%
8,980
T icon
53
AT&T
T
$165B
$1.27M 0.47%
43,386
-319
-0.7% -$8.71K
FMSA
54
DELISTED
Fairmount Santrol Holdings Inc.
FMSA
$1.25M 0.46%
238,500
+500
+0.2% +$2.35K
DELL icon
55
Dell
DELL
$296B
$1.23M 0.45%
53,987
-958
-2% -$21.7K
NXPI icon
56
NXP Semiconductors
NXPI
$58.9B
$1.17M 0.43%
9,958
-4,177
-30% -$482K
BMY icon
57
Bristol-Myers Squibb
BMY
$132B
$1.13M 0.42%
18,488
+780
+4% +$48.8K
DLR icon
58
Digital Realty Trust
DLR
$70.8B
$1.09M 0.4%
9,550
+3,110
+48% +$366K
KMB icon
59
Kimberly-Clark
KMB
$35.9B
$1.01M 0.37%
8,347
+400
+5% +$46.7K
CL icon
60
Colgate-Palmolive
CL
$74.3B
$994K 0.37%
13,175
SJM icon
61
J.M. Smucker
SJM
$12.6B
$965K 0.36%
7,770
+550
+8% +$61.1K
WTW icon
62
Willis Towers Watson
WTW
$31.9B
$930K 0.34%
6,170
MDT icon
63
Medtronic
MDT
$114B
$923K 0.34%
11,435
+361
+3% +$28.9K
LLY icon
64
Eli Lilly
LLY
$1.1T
$921K 0.34%
10,903
BRK.B icon
65
Berkshire Hathaway Class B
BRK.B
$1.13T
$909K 0.33%
4,587
ADP icon
66
Automatic Data Processing
ADP
$109B
$899K 0.33%
7,673
-200
-3% -$22.9K
RTX icon
67
RTX Corp
RTX
$302B
$874K 0.32%
10,891
+240
+2% +$18.2K
RDS.A
68
DELISTED
Royal Dutch Shell PLC ADS Class A
RDS.A
$873K 0.32%
13,090
-420
-3% -$26.5K
PSX icon
69
Phillips 66
PSX
$86B
$843K 0.31%
8,333
BNY
70
Bank of New York Mellon
BNY
$108B
$792K 0.29%
14,701
STT icon
71
State Street
STT
$51.3B
$784K 0.29%
8,033
ENSV
72
DELISTED
Enservco Corp.
ENSV
$750K 0.28%
77,620
+917
+1% +$8.32K
JPM icon
73
JPMorgan Chase
JPM
$956B
$725K 0.27%
6,780
+1,979
+41% +$200K
WWW icon
74
Wolverine World Wide
WWW
$1.55B
$721K 0.27%
22,615
WBA
75
DELISTED
Walgreens Boots Alliance
WBA
$719K 0.26%
9,900

Similar funds

Hunter Associates Investment Management's Q4 2017 Portfolio in Review

As of Q4 2017, Hunter Associates Investment Management held 170 positions worth $271M, up 5.8% from $257M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Hunter Associates Investment Management's Q4 2017 filing shows 10 new, 48 increased, 63 reduced and 6 closed positions. Its largest new stake was Aptiv: 32,895 shares worth $2.79M. The largest sale was Enterprise Products Partners, an estimated $1.9M.

By sector, the portfolio is most concentrated in Healthcare at 23% of assets, down from 24% a quarter earlier, followed by Technology and Industrials.

  • Hunter Associates Investment Management's largest Q4 2017 buy was Aptiv: 32,895 shares worth $2.79M.
  • Hunter Associates Investment Management added most to Amgen in Q4 2017, an estimated $1.13M increase.
  • Hunter Associates Investment Management's biggest Q4 2017 reduction was Enterprise Products Partners, cutting an estimated $1.9M.
  • Hunter Associates Investment Management fully exited Neos Therapeutics, Inc in Q4 2017, selling an estimated $457K.
  • Hunter Associates Investment Management's ten largest holdings make up 32% of its $271M portfolio in Q4 2017.
  • Hunter Associates Investment Management opened 10 new positions and closed 6 in Q4 2017.
  • Hunter Associates Investment Management's portfolio value rose 5.8% quarter-over-quarter to $271M.

Based on Hunter Associates Investment Management's 13F filing for Q4 2017, filed 15 Feb 2018.